

FIG. 1




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12

				ARID1A mutations	Compound 1 response
Colon Cancer	Model	Type			
	CR0126	PDX		R1310G	0% {no response}
	CR3398	PDX		R1310G	0% {no response}
	TO-2	PD organoid		R1310G	responder {AUC =67}
	TO-3	PD organoid		G3087R	non-responder {AUC =98}
	TO-4	PD organoid		R1310G	non-responder {AUC =93}
	TO-11	PD organoid		WT	responder {AUC =69}
	TO-12	PD organoid		WT	non-responder {AUC =93}
	TO-13	PD organoid		WT	non-responder {AUC =92}
Gastric Cancer	Model	Type		ARID1A mutations	Compound 1 response
	GA6866	PDX		R1310G	0% {no response}
	TO-1	PD organoid		R1310G	non-responder {AUC =93}
	TO-9	PD organoid		WT	non-responder {AUC =93}
Lung Cancer	Model	Type		ARID1A mutations	Compound 1 response
	TO-5	PD organoid		R1310G	possible responder {AUC =64}
	TO-10	PD organoid		WT	possible responder {AUC =65}
Ovarian Cancer (non-Clear Cell)	Model	Type		ARID1A mutations	Compound 1 response
	OV2029	PDX		R1310G	0% {no response}
	OV5397	PDX		S687* R1310G	0% {no response}

FIG. 13




FIG. 14





FIG. 15



TGI relative
to veh (d27)

Compound I	89% ***
PF-06821497	41% *
Valemetostat	83% ***
MAK683	59% **
Tazemetostat	32% *
CPI-1205	40% *

FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24

